The Series A financing positions Alizé to take a rival to Shire’s Natpara through to clinical proof of concept over the next few years.
Alizé Pharma 3 has raised €67m ($75m) to take two endocrinology and metabolism drugs into human testing and through to the delivery of mid-phase data.
Lyon-based Alizé is the latest venture of Thierry Abribat, a serial entrepreneur who sold his last two companies to
Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?
GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut
Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.
